These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 2471198)

  • 1. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.
    Lederman MM; Purvis SF; Walter EI; Carey JT; Medof ME
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4205-9. PubMed ID: 2471198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
    Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
    Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced complement-susceptibility and dysfunction of lymphocytes in paroxysmal nocturnal haemoglobinuria (PNH).
    Tomiyama J; Ninomiya H; Abe T
    Br J Haematol; 1990 Dec; 76(4):540-4. PubMed ID: 1702310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
    Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H
    J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF).
    Nicholson-Weller A; Russian DA; Austen KF
    J Immunol; 1986 Aug; 137(4):1275-9. PubMed ID: 3090145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
    Kinoshita T; Medof ME; Silber R; Nussenzweig V
    J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: expression on the cells of three complement inhibitory membrane proteins.
    Rooney IA; Morgan BP
    Immunology; 1990 Nov; 71(3):308-11. PubMed ID: 1702747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
    Horta MF; Ramalho-Pinto FJ
    J Exp Med; 1991 Dec; 174(6):1399-406. PubMed ID: 1720809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.
    Nicholson-Weller A; March JP; Rosen CE; Spicer DB; Austen KF
    Blood; 1985 May; 65(5):1237-44. PubMed ID: 2581636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
    Cheung NK; Walter EI; Smith-Mensah WH; Ratnoff WD; Tykocinski ML; Medof ME
    J Clin Invest; 1988 Apr; 81(4):1122-8. PubMed ID: 2450893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    Davitz MA; Low MG; Nussenzweig V
    J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma.
    Fukuda H; Seya T; Hara T; Matsumoto M; Kinoshita T; Masaoka T
    Immunol Lett; 1991 Aug; 29(3):205-9. PubMed ID: 1722775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human complement-dependent cell lysis by bovine aortic endothelial cells transfected with membrane-bound complement-regulatory factor (DAF and HRF20) gene using a retroviral vector.
    Hayashi S; Isobe K; Emi N; Yokoyama I; Okada H; Nakashima I; Takagi H
    Eur Surg Res; 1996; 28(6):440-6. PubMed ID: 8954321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.
    Tate CG; Uchikawa M; Tanner MJ; Judson PA; Parsons SF; Mallinson G; Anstee DJ
    Biochem J; 1989 Jul; 261(2):489-93. PubMed ID: 2476116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis.
    Miyagawa S; Kubo T; Matsunami K; Kusama T; Beppu K; Nozaki H; Moritan T; Ahn C; Kim JY; Fukuta D; Shirakura R
    J Immunol; 2004 Sep; 173(6):3945-52. PubMed ID: 15356143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.